Drug Information

Drug General Information
Drug ID
D0B3RL
Former ID
DIB014291
Drug Name
R-IFN-1a
Indication HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10:B17.1, B18.2] Phase 2 [534317]
Company
Merck-Serono Laboratories
Target and Pathway
Target(s) IFN-alphaR Target Info Modulator [525616]
KEGG Pathway Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Osteoclast differentiation
Toll-like receptor signaling pathway
Jak-STAT signaling pathway
Natural killer cell mediated cytotoxicity
Hepatitis C
Hepatitis B
Measles
Influenza A
Herpes simplex infection
NetPath Pathway TCR Signaling Pathway
Leptin Signaling Pathway
PANTHER Pathway Inflammation mediated by chemokine and cytokine signaling pathway
Pathway Interaction Database Downstream signaling in na&#xef
Reactome Interferon alpha/beta signaling
Regulation of IFNA signaling
WikiPathways Toll-like receptor signaling pathway
Interferon type I signaling pathways
Interferon alpha/beta signaling
Regulation of toll-like receptor signaling pathway
Osteoclast Signaling
References
Ref 534317A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. Br J Cancer. 1997;75(3):423-6.
Ref 525616Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci.1999 Oct 15;168(2):131-6.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.